About Us
Science
Pipeline
Investors
Contact
Careers
Media Coverage
Any Year
October 24, 2023
Episode 24 – Genetic engineering for allogeneic immunotherapy
Drug Target Review
October 13, 2023
The impact of cell therapies on cancer treatments
PMLiVE
September 6, 2023
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies
Exec Edge
August 14, 2023
mRNA-engineered iPSC-derived Cell Therapies Hold Potential for Tackling Solid Tumors
CGTLive
July 5, 2023
The promise of iPSC-based multi-cell therapeutics
Drug Target Review
June 1, 2023
Tapping the Potential of mRNA in Cellular Reprogramming and Beyond
Longevity Technology
May 24, 2023
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel
Exec Edge
May 18, 2023
Kyle Garland, PhD on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid Tumors
CGTLive
May 3, 2023
Eterna Acquires Allogeneic Immuno-Oncology Platform from Exacis
Labiotech
May 2, 2023
Exclusive: RNA Firm Eterna Therapeutics Buys Neighboring Startup for $50M
Boston Business Journal
2 of 2
